Bruker (NASDAQ:BRKR) Stock Price Up 6.9% – Time to Buy?

Bruker Corporation (NASDAQ:BRKR) shares traded up 6.9% on Wednesday . The company traded as high as $61.10 and last traded at $61.2830. 1,753,429 shares were traded during trading, a decline of 27% from the average session volume of 2,395,581 shares. The stock had previously closed at $57.31.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Guggenheim cut their target price on shares of Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Jefferies Financial Group set a $50.00 target price on shares of Bruker in a research note on Thursday, February 12th. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. UBS Group lifted their target price on shares of Bruker from $40.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group dropped their price objective on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research note on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Bruker has an average rating of “Hold” and an average price target of $50.54.

Bruker Price Performance

The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The firm’s 50 day moving average is $40.64 and its 200 day moving average is $42.98. The firm has a market cap of $9.36 billion, a P/E ratio of -254.96, a price-to-earnings-growth ratio of 3.50 and a beta of 1.31.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. During the same quarter in the previous year, the firm posted $0.47 earnings per share. Bruker’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio is currently -83.33%.

Insider Activity

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. Royal Bank of Canada lifted its stake in shares of Bruker by 8.3% in the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after buying an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Bruker in the first quarter worth approximately $262,000. Goldman Sachs Group Inc. lifted its stake in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after buying an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after buying an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth lifted its stake in shares of Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after buying an additional 6,008 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.